IP Library Granted Patent US 11,779,614
Granted Patent B2
US 11,779,614 · App. 16/635,667 · Granted Oct 10, 2023

Probiotic bacteria preconditioned in a GOS-containing medium and use thereof

Inventors: Biljana Bogicevic (Bern, CH); Jeroen Andre Muller (Singapore, SG); Nicolas Page (Lausanne, CH); Guenolee Eliane Marie Prioult (Bern, CH); Wilbert Sybesma (Munsingen, CH); Thomas Sasse (Bern, CH); Benoit Marsaux (Nantes, FR)
Assignee: Societe des Produits Nestle S.A.
A61K35/745A23L33/135A23L33/21A23L33/40A61K35/747A61P1/00C12N1/20A23V2002/00A23Y2220/43A23Y2300/21A23Y2300/29A23Y2300/49A23Y2300/55A61K2035/115C12N2500/30C12N2500/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,614
App. No.
16/635,667
Granted
Oct 10, 2023
Kind
B2
Abstract

The present invention relates to compositions comprising galactooligosaccharides (GOS) and probiotic bacteria obtained by a process comprising the step of growing the bacteria in a medium comprising GOS, such composition having the effect of boosting the synbiotic effect of the probiotic bacteria with the GOS. Health benefits of the probiotic bacteria as obtained by such a fermentation process are also contemplated.

Claims (31)

1. A composition comprising an effective amount of galactooligosaccharides and a probiotic bacteria comprising the galCDEGR(A) operon, wherein the probiotic bacteria is obtained by a process comprising

fermenting the probiotic bacteria in a bacterial growth medium comprising galacto-oligosaccharides, peptone, and at least one of 3′-sialyllactose or 6′-sialyllactose; harvesting the fermented probiotic bacteria, and

adding additional galacto-oligosaccharides to a culture obtained from the harvesting,

and the probiotic bacteria comprises Bifidobacterium.

2. The composition according to claim 1 , wherein the probiotic bacteria is selected from the group consisting of Bifidobacterium animalis ssp. lactis, Bifidobacterium longum and Bifidobacterium breve.

3. The composition according to claim 1 , wherein the probiotic bacteria is selected from the group consisting of Bifidobacterium animalis ssp. lactis deposited as CNCM I-3446, Bifidobacterium longum deposited as ATCC BAA-999, Bifidobacterium longum deposited as ATCC 15707, Bifidobacterium longum deposited as CNCM I-5259, and Bifidobacterium breve deposited as CNCM I-3914.

4. The composition according to claim 1 , wherein the composition comprises at least 0.2% total galacto-oligosaccharides, based on dry matter.

5. The composition according to claim 1 , wherein the probiotic bacteria is present in an amount of at least 5×10 5 cfu/g.

6. The composition according to claim 1 , wherein the composition is selected from the group consisting of a food product, a beverage, an animal feed product, a nutritional supplement for human or animal, a pharmaceutical composition, and a cosmetic composition.

7. The composition according to claim 6 , which is a nutritional composition selected from the group consisting of infant formula, infant cereals, follow-up formula, growing-up milks, functional milks, and milk products for pregnant and lactating women or for women desiring to get pregnant.

8. A probiotic bacteria comprising the galCDEGR(A) operon, the probiotic bacteria obtained by a process comprising

fermenting the probiotic bacteria in a bacterial growth medium comprising galacto-oligosaccharides, peptone, and at least one of 3′-sialyllactose or 6′-sialyllactose; harvesting the fermented probiotic bacteria, and

adding additional galacto-oligosaccharides to a culture obtained from the harvesting,

and the probiotic bacteria comprises Bifidobacterium.

9. A process for increasing a therapeutic effect of a composition comprising galactooligosaccharides and a probiotic bacteria comprising the galCDEGR(A) operon, the process comprising:

fermenting the probiotic bacteria in a bacterial growth medium comprising galacto-oligosaccharides, peptone, and at least one of 3′-sialyllactose or 6′-sialyllactose;

harvesting the fermented probiotic bacteria, and

adding additional galacto-oligosaccharides to a culture obtained from the harvesting,

before incorporating the probiotic bacteria into the composition,

and the probiotic bacteria comprises Bifidobacterium.

10. The process according to claim 9 , wherein the therapeutic effect selected from the group consisting of to modulate the immune defenses of a subject, to boost the immune defenses of a subject, to prevent, treat or reduce infections in a subject, to prevent, treat or reduce inflammation in a subject, to prevent allergic reactions in a subject, to promote healthy microbiota in the gastrointestinal tract of a subject, to increase total short chain fatty acid production in the gastrointestinal tract of a subject, to increase acetate production in the gastrointestinal tract of a subject, to increase the production of lactic acid in the gastrointestinal tract of a subject, and to improve the activity of the microbiota in the gastrointestinal tract of a subject.

11. The composition according to claim 1 , wherein the probiotic bacteria comprises Bifidobacterium animalis ssp. Lactis.

12. The probiotic bacteria according to claim 8 comprising Bifidobacterium animalis ssp. Lactis.

13. The process according to claim 9 , wherein the probiotic bacteria comprises Bifidobacterium animalis ssp. Lactis.

14. The composition according to claim 1 , wherein the bacterial growth medium comprises 3′-sialyllactose and 6′-sialyllactose.

15. The composition according to claim 1 , wherein the bacterial growth medium further comprises one or more of lactose, glucose, or galactose.

16. The probiotic bacteria according to claim 8 , wherein the bacterial growth medium comprises 3′-sialyllactose and 6′-sialyllactose.

17. The probiotic bacteria according to claim 8 , wherein the bacterial growth medium further comprises one or more of lactose, glucose, or galactose.

18. The process according to claim 9 , wherein the bacterial growth medium comprises 3′-sialyllactose and 6′-sialyllactose.

19. The process according to claim 9 , wherein the bacterial growth medium further comprises one or more of lactose, glucose, or galactose.

20. The process according to claim 9 , wherein the probiotic bacteria comprises Bifidobacterium animalis ssp. Lactis deposited as CNCM I-3446.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2022
From: BOGICEVIC, BILJANA; MULLER, JEROEN ANDRE; PAGE, NICOLAS; PRIOULT, GUENOLEE ELIANE MARIE; SYBESMA, WILBERT
To: NESTEC S.A.
Reel/Frame 059471/0056 →
MERGER Recorded Apr 1, 2022
From: NESTEC S.A.
To: SOCIETE DES PRODUITS NESTLE S.A.
Reel/Frame 059471/0174 →
Priority Claims (2)
EP 17185017 · Aug 4, 2017 · regional
EP 17202142 · Nov 16, 2017 · regional
Continuity (1)
Related Publication 20210121507A1 · Apr 29, 2021